MedWatch

Hovione enters partnership with Zerion Pharma

A partnership between global contract manufacturer Hovione and Zerion Pharma is a validation of the company’s technology that can increase the solubility of oral drugs, says the latter company’s CEO, Ole Wiborg, who is pleased about acquiring a global partner committed to delivering a number of projects.

Ole Wiborg, CEO of Zerion Pharma | Photo: Zerion Pharma/PR

Zerion Pharma, which is focused on improving existing drugs’ effect by increasing the solubility of oral medications, has entered a strategic partnership with Hovione, which is a global contract development and manufacturing organization (CDMO) dealing with generic drugs.

The partnership’s purpose is to penetrate the global market, and CEO at Zerion Pharma Ole Wiborg hopes that the company’s technology can be spread out to the entire world with the new partner in hand.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs